Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial

by Winston, Alan, and Puls, Rebekah, CSF Sub-study, group Encore
Published 2014

Assessing site performance in the Altair study, a multinational clinical trial

by Berthon-Jones, Nisha, Courtney-Vega, Kymme, Donaldson, Anna, Haskelberg, Hila, Emery, Sean, Puls, Rebekah
Published 2015

Differences in the Direction of Change of Cerebral Function Parameters Are Evident over Three Years in HIV-Infected Individuals Electively Commencing Initial cART

by Winston, Alan, Puls, Rebekah, Kerr, Stephen J., Duncombe, Chris, Li, Patrick, Gill, John M., Ramautarsing, Reshmie, Taylor-Robinson, Simon D., Emery, Sean, Cooper, David A.
Published 2015

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results o...

by Dickinson, Laura, Amin, Janaki, Else, Laura, Boffito, Marta, Egan, Deirdre, Owen, Andrew, Khoo, Saye, Back, David, Orrell, Catherine, Clarke, Amanda, Losso, Marcelo, Phanuphak, Praphan, Carey, Dianne, Cooper, David A., Emery, Sean, Puls, Rebekah
Published 2015